HC Wainwright Forecasts Strong Price Appreciation for Repligen (NASDAQ:RGEN) Stock

Repligen (NASDAQ:RGEN) had its target price hoisted by stock analysts at HC Wainwright from $180.00 to $208.00 in a report released on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 82.65% from the stock’s current price.

Other analysts also recently issued research reports about the stock. Barclays reduced their price target on shares of Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Weiss Ratings cut Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, March 3rd. Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. KeyCorp restated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Finally, Wells Fargo & Company cut their target price on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and an average price target of $176.92.

Repligen Trading Down 3.2%

Shares of Repligen stock opened at $113.88 on Monday. The company has a 50-day moving average of $140.22 and a two-hundred day moving average of $146.90. Repligen has a 12-month low of $102.96 and a 12-month high of $175.77. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. The stock has a market cap of $6.41 billion, a PE ratio of 133.98, a price-to-earnings-growth ratio of 2.23 and a beta of 1.14.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The firm had revenue of $197.91 million during the quarter, compared to the consensus estimate of $192.23 million. During the same period last year, the business posted $0.44 EPS. Repligen’s quarterly revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, research analysts anticipate that Repligen will post 1.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Repligen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhenman & Partners Asset Management AB boosted its stake in Repligen by 333.3% in the 2nd quarter. Rhenman & Partners Asset Management AB now owns 19,500 shares of the biotechnology company’s stock worth $2,425,000 after buying an additional 15,000 shares during the last quarter. XTX Topco Ltd increased its stake in shares of Repligen by 34.1% during the 2nd quarter. XTX Topco Ltd now owns 17,352 shares of the biotechnology company’s stock valued at $2,158,000 after acquiring an additional 4,417 shares during the last quarter. Iron Triangle Partners LP purchased a new position in shares of Repligen during the 3rd quarter worth about $36,091,000. Delta Investment Management LLC purchased a new position in shares of Repligen during the 3rd quarter worth about $6,779,000. Finally, Congress Asset Management Co. boosted its position in shares of Repligen by 43.4% in the third quarter. Congress Asset Management Co. now owns 218,592 shares of the biotechnology company’s stock worth $29,219,000 after acquiring an additional 66,142 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.